A peptide that folds itself into spider-web nanofibers around a cancer cell's mitochondria produced 3.7 times more of a cell-killing molecule than the same peptide left floating loose, according to a study of brain tumors in mice.
The work, published in the Proceedings of the National Academy of Sciences ↗, takes on glioma, an aggressive brain tumor that runs on an unusually heavy energy budget. That hunger is also a weakness. Wreck a glioma cell's mitochondria, the power plants that feed it, and the cell struggles to keep growing.
The trick
The tool is a treatment called sonodynamic therapy. A drug that does nothing on its own, a sonosensitizer, is given first, and focused ultrasound aimed through the skull switches it on only where the sound waves converge. Where it turns on, it spins out reactive oxygen species (ROS), the corrosive molecules that damage a cell from the inside. Ultrasound reaches deep into the brain without a cut, which is why the approach is attractive for a tumor buried under the skull.
The researchers built a peptide they call P1, hung light-absorbing porphyrin groups on it, and borrowed a design idea from spiders. Inside a glioma cell, P1 assembles into web-like nanofibers that wrap around the mitochondria and release ROS right at the surface. Packed together as fibers rather than scattered as single molecules, the peptide generated 3.7 times as much ROS. Ultrasound sped up the self-assembly.
Getting it into the brain
The harder problem is delivery. The blood-brain barrier keeps most drugs out of brain tissue, and a brain tumor is doubly hard to reach. The team loaded P1 into exosomes, the tiny membrane bubbles that cells shed, harvested from glioma cells themselves, and called the loaded carrier Evs@P1. Those glioma-derived carriers crossed the barrier better and homed back to glioma tissue, a same-cell-type targeting trick. Once a tumor cell swallowed a carrier, the acidic interior of its lysosome broke the package open and freed the mitochondria-seeking peptide to do its work. In mice, the loaded exosomes held back tumor growth in the brain.
What to make of it
This is a mouse study with an engineered peptide, not a therapy anyone can get. The exosome supply chain alone, growing tumor cells to harvest their bubbles, is a long way from a manufacturable product, and porphyrin sonosensitizers have their own history of slow clinical translation.
What is worth watching is the combination. A self-assembling peptide that concentrates its own payload, a carrier that slips the blood-brain barrier, and an on-switch that only fires where the ultrasound is pointed together describe a fairly specific way to hit a tumor and spare the rest of the brain. Mitochondria-targeting peptides are a small but growing category, and the anticancer ↗ and mitochondrial ↗ corners of peptidemodel are where a design like this one would sit if it ever leaves the mouse.